AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 DEC 29 - (NewsRx.com & NewsRx.net) -- Chemokines and their downstream signaling may be novel therapeutic targets in osteoarthritis.
According to published research from Italy, "Besides the well-known activities of the prototypical inflammatory cytokines (IL-1beta, TNF-alpha), a role for chemokines and their receptors in cartilage degradation in osteoarthritis has recently been reported. Human chondrocytes can produce CC and CXC chemokines and express chemokine receptors for both chemokine subfamilies. Engagement of these receptors can induce the release of matrix degrading enzymes such as matrix metalloproteinases 1, 3, and 13, and N-acetyl-beta-D-glucosaminidase."
"Furthermore GROalpha, a CXC chemokine acting on CXCR2, can activate an apoptotic pathway in chondrocytes that leads to chondrocyte cell death," wrote R.M. Borzi and colleagues.
The researchers concluded: "These findings suggest that chemokines can act as an autocrine or paracrine loop on chondrocytes and can contribute to many ...